Work

Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastatic prostate cancer (ADMPC).

Year: 2011

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.29.7_suppl.137

Authors: M. N. Stein, I. Khan, M. Hussain, G. Liu, G. Wilding, E. M. Posadas, W. M. Stadler, C. Jeyamohan, S. Eddy, R. S. DiPaola

Institutions: University of Michigan, University of Chicago Medical Center, University of Wisconsin Carbone Cancer Center, Rutgers Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2560619103

Cites:

Cited by: 3

Related to: 10